Skip to main content

ASCO 2021 - Breast Cancer

Lack of genetic counseling referrals in women diagnosed with breast cancer contribute to a gap between the need for and completion of genetic testing, reducing access to more personalized therapies for these patients. Read More ›

Alpelisib activity improves real-world progression-free survival in breast cancer patients with PI3KCA mutations when used in combination with fulvestrant compared with fulvestrant alone. Read More ›

Research indicates no significant improvement in breast cancer–specific survival in male breast cancer in the past 30 years. Read More ›

Prognostic understanding may be associated with hospitalization or hospice use depending on how patients were queried about their prognosis and whether oncologists’ estimates were considered. Read More ›

Electronic patient-reported outcome remote monitoring of patients receiving parenteral cancer therapy in routine clinical care is feasible. Office intervention may reduce the need for emergency and inpatient services. Read More ›

Page 2 of 2